Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 10;10(11):e037555.
doi: 10.1136/bmjopen-2020-037555.

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial

Michael J R Desborough  1 , Rustam Al-Shahi Salman  2 , Simon J Stanworth  3   4   5 , Diane Havard  6   7 , Paul M Brennan  2 , Robert A Dineen  6   7 , Timothy J Coats  8 , Trish Hepburn  9 , Philip M Bath  6   7 , Nikola Sprigg  10   7
Affiliations

Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial

Michael J R Desborough et al. BMJ Open. .

Abstract

Introduction: Intracerebral haemorrhage (ICH) can be devastating and is a common cause of death and disability worldwide. Pre-ICH antiplatelet drug use is associated with a 27% relative increase in 1 month case fatality compared with patients not using antithrombotic drugs. We aim to assess the feasibility of conducting a randomised controlled testing the safety and efficacy of desmopressin for patients with antiplatelet-associated ICH.

Methods and analysis: We aim to include 50 patients within 24 hours of spontaneous ICH onset, associated with oral antiplatelet drug(s) use in at least the preceding 7 days. Patients will be randomised (1:1) to receive intravenous desmopressin 20 µg in 50 mL sodium chloride 0.9% infused over 20 min or matching placebo. We will mask participants, relatives and outcome assessors to treatment allocation. Feasibility outcomes include proportion of patients approached being randomised, number of patients receiving allocated treatment, rate of recruitment and adherence to treatment and follow-up. Secondary outcomes include change in ICH volume at 24 hours; hyponatraemia at 24 hours, length of hospital stay, discharge destination, early death less than 28 days, death or dependency at day 90, death up to day 90, serious adverse events (including thromboembolic events) up to day 90; disability (Barthel index, day 90), quality of life (EuroQol 5D (EQ-5D), day 90), cognition (telephone mini-mental state examination day 90) and health economic assessment (EQ-5D).

Ethics and dissemination: The Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH) trial received ethical approval from the East Midlands-Nottingham 2 research ethics committee (18/EM/0184). The DASH trial is funded by National Institute for Health and Care Research RfPB grant: PB-PG-0816-20011. Trial results will be published in a peer reviewed academic journal and disseminated through academic conferences and through patient stroke support groups. Reporting will be in compliance with Consolidated Standards of Reporting Trials recommendations.

Trial registration numbers: NCT03696121; ISRCTN67038373; EudraCT 2018-001904-12.

Keywords: anticoagulation; bleeding disorders & coagulopathies; clinical trials; stroke; stroke medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flowchart.
See this image and copyright information in PMC

References

    1. GBD 2015 Mortality and Causes of Death Collaborators Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet 2016;388:1459–544. 10.1016/S0140-6736(16)31012-1 - DOI - PMC - PubMed
    1. GBD 2017 DALYs and HALE Collaborators Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1859–922. 10.1016/S0140-6736(18)32335-3 - DOI - PMC - PubMed
    1. Royal College of Physicians Sentinal stroke national audit programme (SSNAP). Royal College of Physicians, 2016.
    1. Lovelock CE, Molyneux AJ, Rothwell PM, et al. . Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol 2007;6:487–93. 10.1016/S1474-4422(07)70107-2 - DOI - PubMed
    1. Thompson BB, Béjot Y, Caso V, et al. . Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology 2010;75:1333–42. 10.1212/WNL.0b013e3181f735e5 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances